These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23172094)

  • 21. Recognition and treatment of response fluctuations in Parkinson's disease: review article.
    Verhagen Metman L
    Amino Acids; 2002; 23(1-3):141-5. PubMed ID: 12373528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Systematic evaluation on influence of dopaminergic therapy: on motor complications in Parkinson's disease].
    Zhou MZ; Liu ZG; Chen W; Lu LX; Wu JY; Qi C
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):438-44. PubMed ID: 19567089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
    Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management for motor and non-motor complications in late Parkinson's disease.
    Chan DK; Cordato DJ; O'Rourke F
    Geriatrics; 2008 May; 63(5):22-7. PubMed ID: 18447408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
    Pagonabarraga J; Rodríguez-Oroz MC
    Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in the pharmacologic management of early Parkinson disease.
    Hauser RA; Zesiewicz TA
    Neurologist; 2007 May; 13(3):126-32. PubMed ID: 17495756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Advanced Parkinson's disease: clinical characteristics and treatment (part 1)].
    Kulisevsky J; Luquin MR; Arbelo JM; Burguera JA; Carrillo F; Castro A; Chacón J; García-Ruiz PJ; Lezcano E; Mir P; Martinez-Castrillo JC; Martínez-Torres I; Puente V; Sesar A; Valldeoriola-Serra F; Yañez R
    Neurologia; 2013 Oct; 28(8):503-21. PubMed ID: 23856182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathophysiology of motor fluctuations in Parkinson's disease.
    Widnell K
    Mov Disord; 2005; 20 Suppl 11():S17-22. PubMed ID: 15822108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levodopa strengths and weaknesses.
    Jankovic J
    Neurology; 2002 Feb; 58(4 Suppl 1):S19-32. PubMed ID: 11909982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decisions under risk in Parkinson's disease: preserved evaluation of probability and magnitude.
    Sharp ME; Viswanathan J; McKeown MJ; Appel-Cresswell S; Stoessl AJ; Barton JJ
    Neuropsychologia; 2013 Nov; 51(13):2679-89. PubMed ID: 23954375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. When should levodopa therapy be initiated in patients with Parkinson's disease?
    Halkias IA; Haq I; Huang Z; Fernandez HH
    Drugs Aging; 2007; 24(4):261-73. PubMed ID: 17432922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease.
    Kumar A; Mann S; Sossi V; Ruth TJ; Stoessl AJ; Schulzer M; Lee CS
    Brain; 2003 Dec; 126(Pt 12):2648-55. PubMed ID: 12937076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survey on general knowledge on Parkinson's disease in patients with Parkinson's disease and current clinical practice for Parkinson's disease among general neurologists from Southwest China.
    Li J; Chen D; Song W; Chen K; Cao B; Huang R; Yang R; Shang H
    Clin Neurol Neurosurg; 2014 Mar; 118():16-20. PubMed ID: 24529223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dysphagia in Parkinson's disease is responsive to levodopa.
    Sutton JP
    Parkinsonism Relat Disord; 2013 Mar; 19(3):282-4. PubMed ID: 23333537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Swallowing improvement after levodopa treatment in idiopathic Parkinson's disease: lack of evidence.
    Melo A; Monteiro L
    Parkinsonism Relat Disord; 2013 Mar; 19(3):279-81. PubMed ID: 23231973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Non-motor fluctuations in Parkinson's disease].
    Levin OS; Smolentseva IG; Ivanov AK
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(3):90-6. PubMed ID: 20607929
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.